Ono Announces Encouraging Efficacy Signals Of ONO-2808, A S1P5 Receptor Agonist, In An Interim Analysis Of Ongoing Phase 2 Clinical Trial In Patients With Multiple System Atrophy

Ono Pharmaceutical Co Ltd :ONO ANNOUNCES ENCOURAGING EFFICACY SIGNALS OF ONO-2808, A S1P5 RECEPTOR AGONIST, IN AN INTERIM ANALYSIS OF ONGOING PHASE 2 CLINICAL TRIAL IN PATIENTS WITH MULTIPLE SYSTEM ATROPHYONO PHARMACEUTICAL: MSA TENDED TO BE SLOWER IN ONO-2808 GROUP IN TERMS OF CLINICAL OUTCOME ENDPOINTONO PHARMACEUTICAL CO LTD: ALL DOSES WERE WELL TOLERATED WITH MANAGEABLE SAFETY PROFILE